High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Phase 2 Completed 102 enrolled Stanford University

NaSingle-groupOpen-labelTreatment

Summary

This study uses a sequence of high-dose chemotherapy drugs and a stem cell transplant to treat multiple myeloma. The study is being performed to evaluate the efficacy and side effects of treatment. Specifically, the study is designed to reduce the risk of interstitial pneumonitis.

Timeline

Start: 2006-08
Primary completion: 2009-04
Completion: 2010-04

Publications

Results Chen AI, Negrin RS, McMillan A, Shizuru JA, Johnston LJ, Lowsky R, Miklos DB, Arai S, Weng WK, Laport GG, Stockerl-Goldstein K. Tandem chemo-mobilization followed by high-dose melphalan and carmustine with single autologous hematopoietic cell transplantation for multiple myeloma. Bone Marrow Transplant. 2012 Apr;47(4):516-21. doi: 10.1038/bmt.2011.106. Epub 2011 May 23.

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Cyclophosphamide	Other / unclassified	—	Intravenous
Subject	Etoposide	Small molecule	—	—
Subject	Melphalan	Small molecule	200 mg/m2	—
Subject	carmustine	Small molecule	15 mg/kg	Intravenous
Background	filgrastim	Protein / enzyme biologic	—	Subcutaneous

High-Dose Sequential Therapy and Single Autologous Transplantation for Multiple Myeloma

Summary

Timeline

Publications

Drugs

Indications